Understanding the molecular mechanisms behind aggressive colorectal cancer
Molecular mechanisms driving mesenchymal colorectal cancer
This study is looking at how certain proteins in the body might help prevent a tough type of colorectal cancer, and it's for anyone interested in understanding how we can find better treatments for this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11025897 on NIH RePORTER |
What this research studies
This research investigates the molecular and cellular mechanisms that contribute to a particularly aggressive form of colorectal cancer characterized by a stem-mesenchymal phenotype. The study focuses on two atypical protein kinases, PKCζ and PKCλ/ι, which are believed to act as tumor suppressors. By using a new mouse model, researchers will explore how the loss of these proteins leads to the development of highly aggressive tumors with immunosuppressive characteristics. The findings aim to uncover potential therapeutic targets for improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mesenchymal colorectal cancer, particularly those with poor prognostic indicators.
Not a fit: Patients with early-stage or non-mesenchymal forms of colorectal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that specifically target aggressive colorectal cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting molecular mechanisms in cancer, suggesting that this approach may yield significant insights and advancements.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Moscat, Jorge — Weill Medical Coll of Cornell Univ
- Study coordinator: Moscat, Jorge
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.